Octreotide News and Research RSS Feed - Octreotide News and Research

Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV [More]
Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Ectopic tumours secreting corticotropin-releasing hormone and adrenocorticotropic hormone are very rare in children and can result in a misdiagnosis of Cushing’s disease, say researchers. [More]
Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later. [More]
Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy. [More]
Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. [More]
FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. [More]
Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours. [More]
FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention. [More]
Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. [More]
Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. [More]
New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

Chiasma, Inc., a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma's Chairman & CEO. [More]
Researchers use metal complexes to modify peptide hormones

Researchers use metal complexes to modify peptide hormones

Researchers at the RUB and from Berkeley have used metal complexes to modify peptide hormones. In the Journal of the American Chemical Society, they report for the first time on the three-dimensional structure of the resulting metal-peptide compounds. [More]
New research into treatment, prognosis and early detection of GI cancers

New research into treatment, prognosis and early detection of GI cancers

New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif. [More]
Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
New guidelines for the treatment of acromegaly, a serious growth hormone disorder

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages. [More]
Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate. [More]
Endo fourth quarter total revenues increase 31% to $511 million

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010. [More]
AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2010. [More]